http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-100434-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f7ef808c841970813e86c82c25c4856
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
filingDate 2009-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65ccc7d8a7721d243c56c8e9153ee12d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62117f5e6c66184986421f3aa48084ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad17d5a479685986157c47eb2b67e76c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e5880233f463eddb244cba18e5c9de1
publicationDate 2012-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber UA-100434-C2
titleOfInvention METHOD OF TREATMENT WITH THE APPLICATION OF EPROSARTAN
abstract The invention relates to the treatment of disorders modulated by blocking of angiotensin II (III) receptors selected from hypertension, congestive heart failure, renal failure and combinations thereof, using eprosartanic acid at a daily dose of 420-480 mg.
priorityDate 2008-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565336
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID183
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281037
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45266664
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505696
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448475405
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID50989844
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24179

Total number of triples: 39.